Skip to main content
. 2021 May 31;19(2):341–354. doi: 10.9758/cpn.2021.19.2.341

Fig. 3.

Fig. 3

Mean change of Montgomery-Åsberg depression rating scale (MADRS) at (A) 2−4 hours, (B) 24 hours, (C) week 1, and (D) week 3−4 between intranasal esketamine and placebo in patients with treatment resistant depression (TRD). Std., standard deviation; CI, confidence interval; IV, inverse variance. aUnpublished study.